Back
Madrigal Pharmaceuticals Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.26/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
64
MDGL
Madrigal Pharmaceuticals
Last Price:
347.27
Seasonality Move:
43.27%
7 Day Trial
ALL ACCESS PASS
$
7
Trade on Tuesday. Profit on Friday. Rinse & Repeat
Get the full details now.Madrigal Pharmaceuticals Price Quote
$347.27
-0.18 (5.48%)
(Updated: November 23, 2024 at 5:44 AM ET)
Madrigal Pharmaceuticals Key Stats
Buy
64
Madrigal Pharmaceuticals (MDGL)
is a Buy
Day range:
$322.73 - $351.07
52-week range:
$168.25 - $368.29
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
9.75%
Volume:
537.2K
Avg. volume:
540.7K
1-year change:
82.41%
Market cap:
$7.6B
Revenue:
$0
EPS:
$-25.12
How Much Does Madrigal Pharmaceuticals Make?
Data Unavailable
Is Madrigal Pharmaceuticals Growing As A Company?
Data Unavailable
Madrigal Pharmaceuticals Stock Price Performance
-
Did Madrigal Pharmaceuticals Stock Go Up Last Month?
Madrigal Pharmaceuticals share price went up by 70.66% last month -
Did MDGL's Share Price Rise Over The Last Year?
MDGL share price rose by 82.41% over the past 1 year
What Is Madrigal Pharmaceuticals 52-Week High & Low?
-
What Is Madrigal Pharmaceuticals’s 52-Week High Share Price?
Madrigal Pharmaceuticals has traded as high as $368.29 over the past 52 weeks -
What Is Madrigal Pharmaceuticals’s 52-Week Low Share Price?
Madrigal Pharmaceuticals has traded as low as $168.25 over the past 52 weeks
Madrigal Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Madrigal Pharmaceuticals?
-
How Much Debt Does Madrigal Pharmaceuticals Have?
Total long term debt quarterly is $117.1M -
How Much Cash Does Madrigal Pharmaceuticals Have?
Cash and short term investments quarterly total is $998.6M -
What Is Madrigal Pharmaceuticals’s Book Value Per Share?
Book value per share is 35.64
Is Madrigal Pharmaceuticals Cash Flow Positive?
-
What Is MDGL Cash Flow From Operations?
Cash flow from operations (TTM) is -$431M -
What Is Madrigal Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $1.2B -
What Is Madrigal Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$588.6M
Madrigal Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
MDGL return on invested capital is -74.25% -
What Is Madrigal Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -62.74% -
What Is MDGL Return On Equity?
ROE is a measure of profitability and is -89.04%
Madrigal Pharmaceuticals Earnings Date & Stock Price
-
What Is Madrigal Pharmaceuticals's Stock Price Today?
A single share of MDGL can be purchased today for 347.45 -
What Is Madrigal Pharmaceuticals’s Stock Symbol?
Madrigal Pharmaceuticals trades on the nasdaq under the ticker symbol: MDGL -
When Is Madrigal Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Madrigal Pharmaceuticals is scheduled on February 28, 2025 -
When Is MDGL's next ex-dividend date?
Madrigal Pharmaceuticals's next ex-dividend date is November 24, 2024 -
How To Buy Madrigal Pharmaceuticals Stock?
You can buy Madrigal Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Madrigal Pharmaceuticals Competitors
-
Who Are Madrigal Pharmaceuticals's Competitors?
Below is a list of companies who compete with Madrigal Pharmaceuticals or are related in some way:
Madrigal Pharmaceuticals Dividend Yield
-
What Is MDGL Dividend Yield?
Madrigal Pharmaceuticals’s dividend yield currently is 0% -
What Is Madrigal Pharmaceuticals’s Payout Ratio?
Madrigal Pharmaceuticals’s payout ratio is 0% -
When Did Madrigal Pharmaceuticals Last Pay A Dividend?
The latest dividend pay date is November 24, 2024 -
What Is Madrigal Pharmaceuticals’s Dividend Per Share?
Madrigal Pharmaceuticals pays a dividend of $0.00 per share
Madrigal Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 28.8% |
| Revenue: | 0% | 80.67% |
Analyst Recommendations
| Buy Recommendations: | 9 |
|---|---|
| Hold Recommendations: | 3 |
| Sell Recommendations: | 0 |
| Price Target: | 372.20 |
| Upside from Last Price: | 7.12% |